KR102128027B1 - 클라우딘 6을 발현하는 암 치료용 항체 - Google Patents

클라우딘 6을 발현하는 암 치료용 항체 Download PDF

Info

Publication number
KR102128027B1
KR102128027B1 KR1020207002280A KR20207002280A KR102128027B1 KR 102128027 B1 KR102128027 B1 KR 102128027B1 KR 1020207002280 A KR1020207002280 A KR 1020207002280A KR 20207002280 A KR20207002280 A KR 20207002280A KR 102128027 B1 KR102128027 B1 KR 102128027B1
Authority
KR
South Korea
Prior art keywords
cldn6
antibody
cells
antibodies
cancer
Prior art date
Application number
KR1020207002280A
Other languages
English (en)
Korean (ko)
Other versions
KR20200014436A (ko
Inventor
우구르 사힌
외즐렘 튀레시
미카엘 코슬로브스키
코르덴 발터
슈테판 뵐
마리아 크로이츠베르크
베른트 후브너
미카엘 에르델리안
미카엘 바이첼
Original Assignee
가니메드 파마슈티칼스 게엠베하
요하네스 구텐베르크-유니버시타트 마인츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가니메드 파마슈티칼스 게엠베하, 요하네스 구텐베르크-유니버시타트 마인츠 filed Critical 가니메드 파마슈티칼스 게엠베하
Priority to KR1020207018103A priority Critical patent/KR102430870B1/ko
Priority claimed from PCT/EP2012/001721 external-priority patent/WO2012156018A1/en
Publication of KR20200014436A publication Critical patent/KR20200014436A/ko
Application granted granted Critical
Publication of KR102128027B1 publication Critical patent/KR102128027B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207002280A 2011-05-13 2012-04-20 클라우딘 6을 발현하는 암 치료용 항체 KR102128027B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207018103A KR102430870B1 (ko) 2011-05-13 2012-04-20 클라우딘 6을 발현하는 암 치료용 항체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486071P 2011-05-13 2011-05-13
EP11004004.5 2011-05-13
EP11004004 2011-05-13
US61/486,071 2011-05-13
PCT/EP2012/001721 WO2012156018A1 (en) 2011-05-13 2012-04-20 Antibodies for treatment of cancer expressing claudin 6

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137030171A Division KR102072183B1 (ko) 2011-05-13 2012-04-20 클라우딘 6을 발현하는 암 치료용 항체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207018103A Division KR102430870B1 (ko) 2011-05-13 2012-04-20 클라우딘 6을 발현하는 암 치료용 항체

Publications (2)

Publication Number Publication Date
KR20200014436A KR20200014436A (ko) 2020-02-10
KR102128027B1 true KR102128027B1 (ko) 2020-06-30

Family

ID=65681287

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002280A KR102128027B1 (ko) 2011-05-13 2012-04-20 클라우딘 6을 발현하는 암 치료용 항체

Country Status (7)

Country Link
JP (2) JP6748282B2 (ja)
KR (1) KR102128027B1 (ja)
ES (1) ES2703936T3 (ja)
HU (1) HUE041781T2 (ja)
PT (1) PT3026064T (ja)
SG (1) SG10201911551RA (ja)
TR (1) TR201821021T4 (ja)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057788A1 (en) * 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241578B1 (en) * 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057788A1 (en) * 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)

Also Published As

Publication number Publication date
JP7263294B2 (ja) 2023-04-24
SG10201911551RA (en) 2020-02-27
PT3026064T (pt) 2018-12-17
KR20200014436A (ko) 2020-02-10
TR201821021T4 (tr) 2019-01-21
HUE041781T2 (hu) 2019-05-28
ES2703936T3 (es) 2019-03-13
JP2020186257A (ja) 2020-11-19
JP2020063282A (ja) 2020-04-23
JP6748282B2 (ja) 2020-08-26

Similar Documents

Publication Publication Date Title
JP6637083B2 (ja) 癌の治療のための抗体
KR102126964B1 (ko) 클라우딘 6 특이적 항체
JP6748282B2 (ja) 癌の治療のための抗体
RU2816850C2 (ru) Антитела для лечения раковых заболеваний, при которых экспрессируется клаудин 6

Legal Events

Date Code Title Description
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
A107 Divisional application of patent
GRNT Written decision to grant